Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Non Operating Income: 2019-2025

Historic Non Operating Income for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $3.5 million.

  • Allogene Therapeutics' Non Operating Income fell 36.12% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 94.84%. This contributed to the annual value of $16.1 million for FY2024, which is 190.00% up from last year.
  • Per Allogene Therapeutics' latest filing, its Non Operating Income stood at $3.5 million for Q3 2025, which was down 40.42% from $5.9 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Non Operating Income ranged from a high of $5.9 million in Q2 2025 and a low of -$6.9 million during Q4 2023.
  • For the 3-year period, Allogene Therapeutics' Non Operating Income averaged around $1.7 million, with its median value being $3.5 million (2025).
  • As far as peak fluctuations go, Allogene Therapeutics' Non Operating Income tumbled by 651.22% in 2022, and later spiked by 305.38% in 2024.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' Non Operating Income stood at -$1.8 million in 2021, then tumbled by 101.27% to -$3.6 million in 2022, then slumped by 90.65% to -$6.9 million in 2023, then skyrocketed by 114.34% to $994,000 in 2024, then crashed by 36.12% to $3.5 million in 2025.
  • Its last three reported values are $3.5 million in Q3 2025, $5.9 million for Q2 2025, and $5.5 million during Q1 2025.